Read More

What Now After FDA AdComm Rebuke for Intercept Pharmaceutical? Analyst Says Approval Of Intercept’s ‘OCA In NASH May Never Occur

On Friday, FDA's Gastrointestinal Drugs Advisory Committee voted 12 to 2—with two abstentions—that the benefits of Intercept Pharmaceutical Inc's ICPT Ocaliva 25 mg, also known as Obeticholic acid (OCA), don't outweigh the risks in nonalcoholic steatohepatitis (NASH) 


Read More

Why This Analyst Thinks ‘Fed Pivot Trade’ Could Go Into Overdrive On Friday — It’s Linked To Sept Jobs Data

This week, the market has flattered only to deceive. After starting with two strong sessions, the momentum faded midweek as the data-dependent Federal Reserve kept traders on tenterhooks. Come Friday, traders would get to digest key economic data that could have a say on the central bank’s upcoming rate decisions for the year.